Drug intelligence / Profile preview

ephedrine + caffeine

Development stage
Phase 3
Lead developer
BaskhanBioPharma
Modality
Small Molecules
Administration
Oral
01

Overview

Ephedrine + caffeine is a pharmacological combination primarily used for weight loss and as a stimulant. Ephedrine is a sympathomimetic amine that acts as an agonist at alpha and beta adrenergic receptors, stimulating the release of norepinephrine, which increases thermogenesis and suppresses appetite. Caffeine, a methylxanthine stimulant, inhibits phosphodiesterase enzymes and antagonizes adenosine receptors in the brain, further increasing cAMP levels and enhancing the stimulatory effects of norepinephrine. When used together, these agents have synergistic effects on metabolism, cardiovascular parameters (such as increased heart rate and blood pressure), energy expenditure, fat oxidation, and appetite suppression. The combination has been associated with enhanced weight loss compared to either agent alone but also carries increased risk of adverse cardiovascular events[2][4][8]. This combination is not approved by regulatory agencies for weight loss due to safety concerns.

Other names
ECA stack (when combined with aspirin)ephedra + caffeine (in supplement context)
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)DRD2 (Dopamine D2 Receptor)PDE (Phosphodiesterase family)ADOR (Adenosine receptors)ADRA1 (Alpha-1 adrenergic receptor family)ADRB1 (β1)

Beyond the preview

Go deeper on ephedrine + caffeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ephedrine + caffeine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call